Latest Manufacturing News

Top Shelf International Holdings Ltd has agreed to sell its Campbellfield production assets to Idyll Wine Co for $8 million, aiming to streamline operations and reduce debt. The deal paves the way for a new co-packing partnership post-sale.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

International Graphite advances its vision of a fully integrated graphite supply chain in Western Australia, securing significant government funding and delivering promising drilling and testwork results at its Springdale project.

Australian Silica Quartz Group reports promising gold intersections at Koolyanobbing Metals Project and progresses its Quartz Hill silica project with positive metallurgical results and strategic funding.

Fertoz Limited reports solid Q4 2024 sales despite Canadian permit delays and plans a strategic rebrand to Canadian Phosphate Limited to align with its growth ambitions.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.

RLF AgTech Ltd has retracted previously announced field trial results due to ASX compliance issues, while simultaneously reporting significant debt reduction and ongoing equity raising efforts to support its expanding Australian and Chinese operations.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.